LON:GSK GSK (GSK) Share Price, News & Analysis GBX 1,392.50 +2.00 (+0.14%) As of 07/25/2025 11:50 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesSustainabilityBuy This Stock About GSK Stock (LON:GSK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GSK alerts:Sign Up Key Stats Today's Range 1,386.50▼ 1,399.5050-Day Range 1,344▼ 1,545.9452-Week Range 1,242.50▼ 1,678.68Volume4.94 million shsAverage Volume13.54 million shsMarket Capitalization£56.51 billionP/E Ratio22.49Dividend Yield4.31%Price TargetGBX 1,683.33Consensus RatingHold Company Overview GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Read More GSK Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreGSK MarketRank™: GSK scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingGSK has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageGSK has only been the subject of 4 research reports in the past 90 days.Read more about GSK's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of GSK is 22.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.03.Price to Earnings Ratio vs. SectorThe P/E ratio of GSK is 22.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.41.Price to Earnings Growth RatioGSK has a PEG Ratio of 1.24. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGSK has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GSK. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipGSK is a leading dividend payer. It pays a dividend yield of 4.25%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthGSK does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of GSK is 96.92%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about GSK's dividend. Sustainability and ESG4.4 / 5Environmental Score-1.56 Short InterestThere is no current short interest data available for GSK. News and Social Media1.7 / 5News Sentiment-0.02 News SentimentGSK has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.09 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for GSK this week, compared to 6 articles on an average week.Search InterestOnly 26 people have searched for GSK on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat Follows3 people have added GSK to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GSK insiders have sold 190.19% more of their company's stock than they have bought. Specifically, they have bought £27,328.35 in company stock and sold £79,303.77 in company stock.Percentage Held by InsidersOnly 1.61% of the stock of GSK is held by insiders.Percentage Held by Institutions45.33% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GSK's insider trading history. Receive GSK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address GSK Stock News HeadlinesGSK hails EU approval for blood cancer drug as US regulator waversJuly 25 at 3:46 AM | lse.co.ukGSK rallies Thursday, outperforms marketJuly 24 at 5:43 PM | marketwatch.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.July 27 at 2:00 AM | Porter & Company (Ad)GSK wins EU approval for drug combos containing blood cancer drug BlenrepJuly 24 at 5:43 PM | msn.comGSK's blood cancer drug gets EU approvalJuly 24 at 5:43 PM | msn.comGSK blood cancer drug reapproved by EU regulatorJuly 24 at 5:43 PM | ft.comGSK (LON:GSK) Earns Hold Rating from Deutsche Bank AktiengesellschaftJuly 23, 2025 | americanbankingnews.comBiotech firm to lay off 150 people in Cambridge, move manufacturing to Penn.July 21, 2025 | msn.comSee More Headlines GSK Stock Analysis - Frequently Asked Questions How have GSK shares performed this year? GSK's stock was trading at GBX 1,346.50 at the beginning of the year. Since then, GSK stock has increased by 3.4% and is now trading at GBX 1,392.50. How were GSK's earnings last quarter? GSK plc (LON:GSK) posted its earnings results on Wednesday, April, 30th. The company reported $44.90 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a trailing twelve-month return on equity of 18.08%. How do I buy shares of GSK? Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of GSK own? Based on aggregate information from My MarketBeat watchlists, some other companies that GSK investors own include AstraZeneca (AZN), Vodafone Group Public (VOD), Lloyds Banking Group (LLOY), Secure Trust Bank (STB), Barclays (BARC), Meta Platforms (META) and Intel (INTC). Company Calendar Last Earnings4/30/2025Today7/27/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - General Sub-IndustryPharmaceutical Products Current SymbolLON:GSK CIKN/A Webwww.gsk.com Phone+44-20-80475000FaxN/AEmployees70,212Year FoundedN/APrice Target and Rating Average Price Target for GSKGBX 1,683.33 High Price TargetGBX 2,000 Low Price TargetGBX 1,450 Potential Upside/Downside+20.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)GBX 61.91 Trailing P/E Ratio22.49 Forward P/E Ratio7.91 P/E Growth1.24Net Income£2.50 billion Net Margins8.02% Pretax MarginN/A Return on Equity18.08% Return on Assets9.56% Debt Debt-to-Equity Ratio114.64 Current Ratio0.81 Quick Ratio0.73 Sales & Book Value Annual Sales£31.14 billion Price / Sales1.81 Cash FlowGBX 170.96 per share Price / Cash Flow8.15 Book ValueGBX 329.73 per share Price / Book4.22Miscellaneous Outstanding Shares4,057,829,779Free FloatN/AMarket Cap£56.51 billion OptionableNot Optionable Beta0.31 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (LON:GSK) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.